Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism

Stefano J. Mandriota¹, Linda J. Valentijn², Laurence Lesne¹, David R. Betts³, Denis Marino¹, Mary Boudal-Khosbeen¹, Wendy B. London⁴, Anne-Laure Rougemont⁶, Edward F. Attiyeh⁶, John M. Maris⁶, Michael D. Hogarty⁶, Jan Koster², Jan J. Molenaar², Rogier Versteeg², Marc Ansari¹,⁷,* Fabienne Gumy-Pause¹,⁷,*

¹Department of Pediatrics, CANSEARCH Research Laboratory, Faculty of Medicine, University of Geneva, Geneva, Switzerland
²Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
³Department of Clinical Genetics, Our Lady’s Children’s Hospital, Dublin, Ireland
⁴Division of Pediatric Hematology/Oncology, Harvard Medical School, Dana-Farber/Children’s Hospital Cancer and Blood Disorders Center, Boston, MA, USA
⁵Department of Pathology, University Hospital of Geneva, Geneva, Switzerland
⁶Department of Pediatrics, Children’s Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, PA, USA
⁷Department of Pediatrics, Onco-hematology Unit, University Hospital of Geneva, Geneva, Switzerland
*These authors have contributed equally to this work

Correspondence to:
Stefano J. Mandriota, e-mail: stefano.mandriota@unige.ch
Fabienne Gumy-Pause, e-mail: Fabienne.GumyPause@unige.ch

Keywords: ataxia-telangiectasia mutated, neuroblastoma, MYCN, 11q

Received: December 19, 2014 Accepted: May 14, 2015 Published: May 26, 2015

ABSTRACT

Neuroblastoma, a childhood cancer with highly heterogeneous biology and clinical behavior, is characterized by genomic aberrations including amplification of MYCN. Hemizygous deletion of chromosome 11q is a well-established, independent marker of poor prognosis. While 11q22-q23 is the most frequently deleted region, the neuroblastoma tumor suppressor in this region remains to be identified. Chromosome bands 11q22-q23 contain ATM, a cell cycle checkpoint kinase and tumor suppressor playing a pivotal role in the DNA damage response. Here, we report that haploinsufficiency of ATM in neuroblastoma correlates with lower ATM expression, event-free survival, and overall survival. ATM loss occurs in high stage neuroblastoma without MYCN amplification. In SK-N-SH, CLB-Ga and GI-ME-N human neuroblastoma cells, stable ATM silencing promotes neuroblastoma progression in soft agar assays, and in subcutaneous xenografts in nude mice. This effect is dependent on the extent of ATM silencing and does not appear to involve MYCN. Our findings identify ATM as a potential haploinsufficient neuroblastoma tumor suppressor, whose inactivation mirrors the increased aggressiveness associated with 11q deletion in neuroblastoma.

INTRODUCTION

Neuroblastoma (NB) is the most frequent solid tumor of infancy. It originates from the sympathetic nervous system (most frequently in adrenal glands), accounts for 8–10% of malignancies in childhood, and causes 15% of cancer-related deaths in children. Prognosis in NB is highly variable, ranging from spontaneous regression to highly aggressive disease, often resistant to multimodal therapy. From a cytogenetic point of view, NB characterized by the loss or gain of entire chromosomes often present with favorable prognostic features. In contrast, unbalanced gain or loss of chromosomal regions (in particular, the loss of chromosome 1p or 11q, the gain of 17q, or the amplification of the MYCN oncogene) have been associated with an adverse prognosis. Poor prognosis NB is subdivided into two main groups: NB
with amplification of the MYCN oncogene (20% of cases) and NB with unbalanced loss of chromosome 11q (30–40% of cases). MYCN amplification and 11q loss occur together in NB very rarely (1.7% of cases, as opposed to an expected frequency of 8% if these two events occurred independently) suggesting that these two cytogenetic anomalies might be incompatible, for reasons that are currently unknown [1, 2].

The MYCN gene encodes N-myc, a helix-loop-helix/leucine zipper transcription factor frequently dysregulated in cancer, that controls the expression of several genes involved in cell cycle progression, cellular invasion, metabolism, and apoptosis. The observation that overexpression of MYCN or of its upstream positive regulator LIN28B targeted to the sympathetic adrenergic lineage of transgenic mice leads to the development of tumors closely resembling human NB [3, 4] supports the hypothesis that MYCN amplification causes NB in humans. Whereas MYCN amplification is a powerful prognostic marker in NB, a typical MYCN gene signature is found in both MYCN amplified NB and in a subset of MYCN non-amplified NB having post-transcriptionally stabilized N-myc protein or amplified MYC. This signature was more powerful, as a prognostic marker, than MYCN amplification [5].

Chromosome bands 11q22-q23, the region most frequently lost in NB, contain ATM, the gene mutated in ataxia telangiectasia (AT), an autosomal recessive syndrome characterized by neurodegeneration, oculocutaneous telangiectasia, radiosensitivity, immune deficiency, sterility, strong predisposition to lymphoid cancers and, at the cellular level, cell-cycle checkpoint defects and chromosomal instability. ATM encodes a homonymous Ser/Thr protein kinase that regulates cell cycle checkpoints, DNA repair, and apoptosis in response to DNA double-strand breaks (DSBs) by phosphorylating several hundred-protein substrates including p53 [6, 7]. Among the DSBs ATM responds to are those caused by activated cellular oncogenes, probably through the induction of proliferation stress. Once activated, the ATM pathway leads to cell cycle arrest, apoptosis or cellular senescence, the latter being a condition of permanent cell growth arrest in otherwise metabolically active cells [8]. Interestingly, N-myc downregulates ATM through the induction of miR-421 [9], suggesting that ATM downregulation is part of the MYCN dictated cellular transformation program in NB.

In addition to its prognostic value, 11q deletion might contribute to NB progression through the loss of 11q tumor suppressor(s). To investigate the possibility that alterations in ATM play a role in NB, we analyzed ATM gene status and expression in two panels of NB samples and in NB cell lines. Based on the results obtained, that demonstrated an association between ATM deletion, decreased ATM expression and poor prognosis, we mimicked the observed reduction in ATM expression in three human NB cell lines by stable ATM silencing.

**RESULTS**

**ATM deletion correlates with lower ATM expression, event-free survival (EFS), and overall survival (OS)**

By full exome mutation screening using DHPLC, with the exception of a c.8147T>C (p.Val2716Ala) change, a missense mutation known to be pathogenic [10] in IMR-32 cells, we found no previously identified ATM mutations or gene hypermethylation in a panel of 16 NB cell lines (CHLA-171, IMR-32, LAN-1, NB16, NBL-S, NGP, SK-N-AS, SK-N-DZ, BE-2C, CHLA-79, CHP-212, CHP-901, KCNR, LAN-6, SK-N-FI, SK-N-SH), but several ATM rare variants (having minor allele frequency (MAF) < 0.01) of unknown significance (data not shown). No known ATM mutations, intragenic deletions/duplications or gene hypermethylation were found in a panel of 50 NB specimens (Supplementary Figure S1). The lack of known ATM mutations in this NB series is consistent with previous data [11–13]. The frequency and kind of ATM rare variants detected in NB specimens was similar to that found in a series of 60 healthy controls (data not shown), but 14/50 of the tumor samples or 6/16 of the cell lines considered (NB16, NBL-S, NGP, SK-N-AS, SK-N-DZ, LAN-6) were found to have a complete hemizygous ATM deletion as assessed by multiplex ligation-dependent probe amplification assay (MLPA). ATM deletion in the six NB cell lines was confirmed by ATM FISH (data not shown). Only one tumor had both MYCN amplification and ATM deletion (Supplementary Figure S1). ATM deletion was associated with lower EFS and OS (Figure 1). INSS stage (1, 2, 3 vs 4 and 1, 2 vs 3, 4) is statistically significantly associated with ATM deletion status, whereby ATM deletion is associated with higher stage [stages 1, 2, 3 versus 4 (p = 0.0099); stages 1, 2 versus 3, 4 (p = 0.0242)]. In a second series of NB (reported in ref. [5], plus additional samples) consisting of 110 specimens for which both ATM expression and ATM locus status were available, 11q deletion at the ATM locus correlates with lower EFS and OS (Figure 2, left), and this is independent of MYCN (Supplementary Figure S2). Of the 71 NB retaining ATM in this series, 3 had 11q loss outside the ATM locus. In general, tumors with a positive MYCN-157 gene signature [5] have either MYCN amplification or ATM loss and this correlates with OS and stage (Figure 3A–3C). When excluding MYCN amplified tumors, the prognostic value of ATM loss strongly increases (Figure 3D and Figure 2, centre) and this is independent of stage and MYCN-157 signature (Supplementary Figure S2). Moreover, ATM loss also correlates with lower EFS and OS in tumors with a negative MYCN-157 signature (Figure 2 right). In the NB110 tumor set, ATM mRNA levels were significantly reduced in the specimens carrying loss of ATM (Figure 4A). In cultured NB cell lines, ATM mRNA and protein levels were reduced in the cell lines carrying ATM deletion as assessed by ATM FISH and MLPA (Figure 4B).
Figure 1: EFS and OS by ATM MLPA deletion status in the NB50 tumor set. One patient was excluded because of ATM duplication. Deletion of ATM is significantly associated with lower event-free survival (EFS) and overall survival (OS) by using the Kaplan-Meier methods. Curves were compared using a log-rank test. EFS and OS are expressed as the estimate +/- the standard error. For EFS, the 5-year survival rate for no deletion was 89% ± 7% compared to 32% ± 15% for ATM deletion (p = 0.0002). For OS, the 5-year survival rate for no deletion was 91% ± 6% compared to 47% ± 15% for ATM deletion (p = 0.0017).
Altogether, these results raise the possibility that partial ATM loss might contribute to NB progression and suggest that, if this hypothesis is true, haploinsufficiency, with the consequent reduction in ATM expression, could be the mechanism involved.

Stable ATM silencing promotes NB progression in vitro and in vivo

To investigate the possibility that decreased ATM expression contributes to NB progression, we generated NB cells stably expressing short hairpin (sh) RNAs against ATM. Using this approach, we previously reported the cell-type specific transforming effect of ATM inactivation in human mammary epithelial cells, which mirrors the breast cancer predisposition of AT carriers [14]. For the NB experiments, we selected the SK-N-SH cell line, characterized by the lack of MYCN amplification, diploid ATM gene status and functional ATM and p53 (ref. [15–17]; and Figure 4B).

When compared to controls expressing LacZ shRNA (referred to as SK-N-SH^LacZ), SK-N-SH cells stably expressing ATM shRNA 3650 (referred to as SK-N-SH^ATM-3650) have almost undetectable ATM protein, whereas SK-N-SH cells stably expressing ATM shRNA 4351 (referred to as SK-N-SH^ATM-4351) have an intermediate level of ATM silencing (Figure 5A, upper panel). ATM mRNA levels were correspondingly reduced in SK-N-SH^ATM-3650 and SK-N-SH^ATM-4351 compared to SK-N-SH^LacZ cells (Figure 5A, bottom panel).

In response to DSBs ATM phosphorylates several protein substrates. This is followed by a transcriptional response mediated in part by p53, one of the ATM phosphorylation substrates and transcriptional effectors [18]. To assess whether reduced ATM expression consistently results in defective ATM substrate phosphorylation in response to DSB inducers, we analyzed the phosphorylation of two well-known ATM substrates – NBS1-Ser343 and p53-Ser15 – in SK-N-SH^ATM-3650, SK-N-SH^ATM-4351 or SK-N-SH^LacZ cells treated with neocarzinostatin (NCS), a chromoprotein enediyne antibiotic that specifically induces DSBs [19]. NCS increases NBS1-Ser343 or p53-Ser15 phosphorylation after 30min in SK-N-SH^LacZ cells. In contrast, phosphorylation of these substrates in NCS treated SK-N-SH^ATM-3650 or SK-N-SH^ATM-4351 cells was largely defective (Figure 6A).

CDKN1A is a well-characterized p53 target gene encoding p21/WAF1, a cyclin-dependent kinase inhibitor that mediates p53-induced growth arrest in response to DNA damage [20]. Basal levels of p21/WAF1 were barely detectable in SK-N-SH^LacZ cells and undetectable in SK-N-SH^ATM-3650 and SK-N-SH^ATM-4351 cells (Figure 6A). Four hours after NCS treatment, p21/WAF1 was strongly induced in SK-N-SH^LacZ cells and to a lesser extent in SK-N-SH^ATM-3650 and SK-N-SH^ATM-4351 cells, consistent with defective

**Figure 2:** ATM deletion correlates with lower EFS and OS, independently of MYCN amplification. Event-free survival (EFS) (upper panels) or overall survival (OS) (lower panels) analysis of ATM loss in the whole NB110 tumor set (left), its non-MYCN-amplified subset (center) or its MYCN-157-negative subset after K-means clustering with the MYCN-157 signature (right). p values were from log-rank test.
phosphorylation of p53 (Figure 6A). Thus, as expected on the basis of their reduced level of ATM expression, SK-N-Sh kd-3650 cells and SK-N-Sh kd-4351 cells exhibit defective phosphorylation of NBS1–Ser343 and p53-Ser15 as well as reduced induction of p21/WAF1 in response to NCS.

To investigate the possibility that reduced expression of ATM confers a growth advantage to SK-N-Sh cells in vitro, we compared SK-N-Sh LacZ, SK-N-Sh kd-3650 and SK-N-Sh kd-4351 cells for their capacity to proliferate in the soft agar assay, a well-established method to measure cellular transformation in vitro. In these experiments, SK-N-Sh kd-3650 cells and SK-N-Sh kd-4351 cells form colonies larger than those formed by SK-N-Sh LacZ cells, the effect being more pronounced in SK-N-Sh kd-3650 cells, which have the strongest silencing of ATM (Figure 5A, 5B; 6B). Since, as seen in SK-N-Sh kd-3650 cells, almost complete silencing of ATM strongly promotes growth in agar (Figure 5B), and since SK-N-Sh kd-4351 cells have partial ATM silencing (Figure 5A), one might argue that colonies formed in agar by SK-N-Sh kd-4351 cells originate from a particular cell subpopulation having a level of ATM expression lower than the average, detected by Western Blotting in the whole cell population (Figure 5A). To clarify this point, we picked individual colonies from the soft agar assay, put them back in culture and analyzed them by Western Blotting as soon as they reached confluence. When compared to cultures derived from SK-N-Sh LacZ cell colonies, all the cultures derived from SK-N-Sh kd-4351 cell colonies analyzed retained a detectable level of ATM expression, like the original total cell population (Figure 6C, Figure 5A). In contrast, ATM protein remained undetectable in cultures derived from SK-N-Sh kd-3650 cell colonies (Figure 6C, Figure 5A). Thus, partial silencing of ATM is sufficient to confer a proliferative advantage to SK-N-Sh cells in the soft agar assay.

To investigate the possibility that ATM silencing also confers a growth advantage to SK-N-Sh cells in vivo, we injected SK-N-Sh stable transfectants subcutaneously into Swiss nu/nu mice. In this model, SK-N-Sh kd-3650 cells and SK-N-Sh kd-4351 cells form tumors up to 10-fold larger than those formed by SK-N-Sh LacZ cells (Figure 3). The plots show 11q loss at the ATM locus versus K-means clustering of the NB110 tumor set using the MYCN-157-signature. Tumors were colored for MYCN amplification (A) survival (B) or INSS stage (C). D. Plot showing only non-MYCN-amplified samples colored for survival. p values are from Fisher’s exact test.
larger than those formed by SK-N-SH\textsuperscript{LacZ} cells. Again, the effect was more marked with the SK-N-SH\textsuperscript{kd-3650} subline, having the strongest ATM silencing (Figure 7A, 5A). By immunohistochemistry, the levels of ATM expression were the highest in tumors formed by SK-N-SH\textsuperscript{LacZ} cells, the lowest in tumors formed by SK-N-SH\textsuperscript{kd-3650} cells, and intermediate in tumors formed by SK-N-SH\textsuperscript{kd-4351} cells, thus mirroring the expression pattern observed in the cell lines used for injection (Figure 7C left column; 5A). Histological analysis (hematoxylin and eosin staining, HE) revealed that all tumors formed by SK-N-SH cells, independently of ATM expression levels, were composed of sheets and nests of large cells, with large nuclei and prominent nucleoli, and scant to moderate amounts of cytoplasm, thus resembling undifferentiated large cell neuroblastoma [21] (Figure 7C right column). Consistent with the undifferentiated status of these tumors, the expression of several neuronal genes (MAPT, GAP43, MAP2, APP, NEFL, NEFM, NEFH, NTRK2, SYP, TH) [22–27] exhibits little or no differences in a cDNA microarray comparing SK-N-SH\textsuperscript{kd-3650} cells with SK-N-SH\textsuperscript{LacZ} cells, except that the expression of NEFH was 2.95-fold (mRNA) or 2.0-fold (protein) higher in SK-N-SH\textsuperscript{kd-3650} cells compared with SK-N-SH\textsuperscript{LacZ} cells. Expression of NEFH was not consistently upregulated in SK-N-SH\textsuperscript{kd-4351} cells that also have ATM silencing (Supplementary Figure S3; Figure 5A). Ki67 immunostaining revealed increased proliferation in xenografts carrying ATM silencing at the time of sacrifice (SK-N-SH\textsuperscript{LacZ} tumors: 36.03% ± 1.38; SK-N-SH\textsuperscript{kd-3650} tumors: 43.29% ± 1.61; SK-N-SH\textsuperscript{kd-4351} tumors: 47.09% ± 3.27; pSK-N-SH\textsuperscript{kd-3650} vs SK-N-SH\textsuperscript{LacZ} = 0.005; pSK-N-SH\textsuperscript{kd-4351} vs SK-N-SH\textsuperscript{LacZ} = 0.005; bilateral t-test) (Figure 7B). No metastases were observed in the three experimental groups at the time of dissection (brain, kidney, spleen, heart, liver, or lung) or in the subsequent histological analysis in the axillary or inguinal lymph nodes, heart, liver, or lung by HE staining.

In summary, these results demonstrate (i) that stable silencing of ATM confers a growth advantage to SK-N-SH cells in vitro and in vivo; (ii) that this effect is dependent on the extent of ATM silencing; and (iii) that partial silencing of ATM is sufficient to confer such growth advantage.

As a next step, we sought to determine if ATM silencing confers a growth advantage to additional NB cell lines. We silenced ATM expression in the CLB-Ga NB cell line by the same shRNA strategy. Like SK-N-SH cells, CLB-Ga cells have no MYCN amplification, wild type p53, and functional ATM [15–17].
Experiments with CLB-Ga cells included a third shRNA against ATM (1463). CLB-Ga cells stably expressing this shRNA (referred to as CLB-Ga\textsuperscript{kd-1463}) had the strongest silencing of ATM, whereas CLB-Ga cells expressing ATM shRNA 3650 (referred to as CLB-Ga\textsuperscript{kd-3650}) had an intermediate level of ATM silencing as assessed by Western blotting (Figure 8A, upper panel) and real-time quantitative PCR (Figure 8A, lower panel). Similar to SK-N-SH cells, phosphorylation of NBS1-Ser343 or p53-Ser15 and p21/WAF1 induction were reduced or delayed in CLB-Ga\textsuperscript{kd-1463} and CLB-Ga\textsuperscript{kd-3650} cells in response to NCS, compared to CLB-Ga\textsuperscript{LacZ} cells.
Similar to SK-N-SH cells, ATM silencing confers a growth advantage to CLB-Ga cells in vitro and in vivo (Figure 8C) although the in vivo effect was less marked compared to that observed in SK-N-SH cells (Figure 8C, lower panel). As seen in SK-N-SH cells, the in vitro and in vivo effect of ATM silencing was more marked in the subline with the most pronounced ATM silencing (CLB-Ga\textsuperscript{kd-1463}; Figure 8A, 8C). Tumor histology (HE staining) was similar in the three experimental groups, all the tumors being densely cellular and highly undifferentiated, independent of ATM silencing (Figure 8D, left panel). No metastases were observed in the three experimental groups at the time of dissection or in the subsequent histological analysis (HE staining) in the brain, kidney, spleen, heart, liver, lung, lymph nodes or femurs.

Taken together, these results demonstrate that stable silencing of ATM confers an in vitro and in vivo growth advantage to two different NB cell lines characterized by normal MYCN status and functional ATM/p53. In both cell lines, partial silencing of ATM was sufficient to observe this effect.

The tumor promoting effect of ATM silencing is MYCN independent

As potential mechanisms for the growth advantage observed in SK-N-SH and CLB-Ga cells with stable ATM silencing, we considered several possibilities.

First, we measured the basal levels of cell death in SK-N-SH\textsuperscript{LacZ}, SK-N-SH\textsuperscript{kd-3650} and SK-N-SH\textsuperscript{kd-4351} cell cultures. Annexin V/7-Amino-Actinomycin (7-AAD) staining revealed similar levels of apoptosis in the three cell populations (SK-N-SH\textsuperscript{LacZ}: 5.46% ± 1.28; SK-N-SH\textsuperscript{kd-3650}: 5.91% ± 1.62; SK-N-SH\textsuperscript{kd-4351}: 6.47% ± 1.05; errors indicate SEM; \( n = 3 \)). These results were corroborated by the quantification of the Sub-G1 cell population in cell cycle analyses (SK-N-SH\textsuperscript{LacZ}: 1.14% ± 0.54; SK-N-SH\textsuperscript{kd-3650}: 0.85% ± 0.32; SK-N-SH\textsuperscript{kd-4351}: 1.73%
± 1.46; errors indicate SD; n = 2). Similar, low levels of cell death were observed when measuring the Sub-G1 cell fraction in CLB-Ga stable transfectants (CLB-Ga\(^{LacZ}\): 0.51% ± 0.20; CLB-Ga\(^{1463}\): 1.15% ± 0.48; CLB-Ga\(^{kd-3650}\): 1.32% ± 1.24; errors indicate SD; n = 2) and in GI-ME-N stable transfectants (see below) (GI-ME-N\(^{LacZ}\): 2.01% ± 0.07; GI-ME-N\(^{kd-1463}\): 1.30% ± 0.85; GI-ME-N\(^{kd-3650}\): 2.89% ± 1.16; errors represent SD, n = 2).

Second, since defective DNA repair resulting from \(ATM\) silencing could generate mutations conferring a proliferative advantage, we analyzed the capacity of SK-N-SH cells stably transfected with \(ATM\) shRNA vectors 3650 or 4351, or with LacZ shRNA vector as a control, to resolve histone H2AX-pSer139 nuclear foci in response to NCS. The induction and decay of H2AX-pSer139 nuclear foci in response to low doses of external mutagens is one of the most reliable and best characterized quantitative DNA repair assays [28]. SK-N-SH\(^{kd-3650}\) and CLB-Ga\(^{kd-1463}\) stable transfectants, having strong \(ATM\) silencing resulting in almost undetectable protein (Figure 5A, 8A), exhibit defective repair of NCS induced H2AX-pSer139 nuclear foci, consistent with previous results on \(ATM\) deficient cells [29, 30]. In contrast, partial silencing of \(ATM\) allows SK-N-SH\(^{kd-4351}\) cells and CLB-Ga\(^{kd-3650}\) cells to resolve the NCS induced H2AX-pSer139 nuclear foci with a kinetics comparable to the respective controls. Examples of the results obtained are shown in Figure 9 and Supplementary Figure S4. We conclude that the growth advantage observed in SK-N-SH and CLB-Ga cells with stable \(ATM\) silencing is not necessarily associated with a gross defect in DSB repair.

To further investigate the mechanism by which stable \(ATM\) silencing promotes NB progression, we performed two sets of experiments.

In the first set of experiments we looked at the expression of genes known to play an important role in the initiation or progression of NB. We selected \(MYCN\), \(ALK\), and \(PHOX2B\). By real-time quantitative PCR, the three genes were upregulated in SK-N-SH\(^{kd-4351}\) cells and CLB-Ga\(^{kd-3650}\) cells compared to SK-N-SH\(^{LacZ}\) cells, \(MYCN\) mRNA exhibiting the highest upregulation (2.5-fold). \(ALK\) and \(PHOX2B\) mRNAs were upregulated to a lesser extent (1.8-fold and 1.5-fold,
respectively). Upregulation of \( ALK \) was not statistically significant (Figure 10A). For these reasons, we decided to investigate \( MYCN \) expression and transcriptional activity in more detail.

At the protein level, N-myc was upregulated by 6-fold in SK-N-SH\(^{kd-3650}\) cells compared to SK-N-SH\(^{LacZ}\) cells as assessed by scanning densitometry. N-myc was also upregulated in SK-N-SH\(^{kd-4351}\) cells, carrying a different \( ATM \) shRNA plasmid, thus confirming the specificity of this effect (Figure 10B). N-myc was also upregulated in tumors formed by SK-N-SH\(^{kd-3650}\) cells and SK-N-SH\(^{kd-4351}\) cells, compared to those formed by SK-N-SH\(^{LacZ}\) cells (Figure 10C). Similar but weaker upregulation of N-myc was also observed in CLB-Ga\(^{kd-1463}\) and CLB-Ga\(^{kd-3650}\) cells compared to CLB-Ga\(^{LacZ}\) cells (Figure 10D).

No amplification of \( MYCN \) was observed in SK-N-SH\(^{kd-3650}\), SK-N-SH\(^{kd-4351}\), CLB-Ga\(^{kd-1463}\) or CLB-Ga\(^{kd-3650}\) cells by real-time quantitative PCR of genomic DNA, thus indicating that increased expression of \( MYCN \) in SK-N-SH and CLB-Ga cells with stable \( ATM \) silencing was not due to \( MYCN \) gene amplification (data not shown).

We then looked at \( MYCN \) transcriptional activity through the analysis of the expression of known \( MYCN \) regulated genes. For this analysis, we selected six genes (\( ATAD2, CRTAP, DKC1, MTAP, PRMT1, PTMA \)) known to be upregulated by \( MYCN \), and two genes (\( CLU, CNTN1 \)) known to be downregulated by \( MYCN \) [5, 31]. When compared to their respective controls (SK-N-SH\(^{LacZ}\) or CLB-Ga\(^{LacZ}\) cells), SK-N-SH\(^{kd-3650}\) or SK-N-SH\(^{kd-4351}\) cells, and CLB-Ga\(^{kd-1463}\) or CLB-Ga\(^{kd-3650}\) cells, despite having higher levels of N-myc expression (Figure 10A–10D), did not exhibit consistent corresponding regulation of the selected \( MYCN \) target genes (Figure 10E provides an example of the results obtained). To further investigate
the possibility that N-myc upregulation observed in SK-N-SH and CLB-Ga cells with stable ATM silencing results in a MYCN transcriptional signature, we analyzed the 157 MYCN target gene signature [5] in our cDNA microarray comparing SK-N-SH<sup>kd-3650</sup> cells with SK-N-SH<sup>LacZ</sup> cells. Of the 157 MYCN regulated genes reported [5], 154 were present in our microarray (the 3 absent genes being: C1orf97, FAM85A and LOC442075). Of these, 138 genes exhibit a fold change ≤ ± 1.5. Ten genes (CNTN1, MBNL2, RAD51AP1, RAD54L, RHOC, SESTD1, Ska3, SYNPO2, TP53INP1, UBE2H) exhibit a fold change > ± 1.5 and ≤ ± 2.0. Six genes (CLU, DNER, PDE5A, SUSD5, SYT4, TEX15) exhibit a fold change > ± 2 and ≤ ± 7.99, with only two genes, DNER (downregulated 6.38-fold in SK-N-SH<sup>kd-3650</sup> cells vs SK-N-SH<sup>LacZ</sup> cells; thus consistent with negative regulation by MYCN [5]) and TEX15 (upregulated 2.39-fold in SK-N-SH<sup>kd-3650</sup> cells vs SK-N-SH<sup>LacZ</sup> cells; thus consistent with positive regulation by MYCN [5]) presenting with a statistically significant regulation (<i>p</i> < 0.05, ANOVA).

Subsequent validation of DNER or TEX15 by real-time quantitative PCR confirmed regulation of these two genes by ATM silencing in SK-N-SH<sup>kd-3650</sup> cells vs SK-N-SH<sup>LacZ</sup> cells but not in SK-N-SH<sup>kd-4351</sup> cells or CLB-Ga stable transfectants (data not shown). Similar results were obtained with miR-19a-5p, a member of the miR-17-92 cluster, known to be upregulated by MYC/MYCN [32], whereas another member of the miR-17-92 cluster, namely miR-92a-1-5p, or DKK3, another MYCN regulated gene [33] were not regulated by ATM silencing in SK-N-SH or CLB-Ga cells as assessed by real-time quantitative PCR (Supplementary Figure S5).

Taken together, our results indicate that although very limited and weak signs of MYCN target gene

---

**Figure 9: Induction and repair of H2AX-pSer139 nuclear foci in NCS treated CLB-Ga stable transfectants.** Approximately 70% confluent cultures of CLB-Ga cells stably transfected with ATM shRNA vectors 1463, 3650 or with a LacZ shRNA vector as a control were stained for H2AX-pSer139 nuclear foci at the indicated times after treatment with NCS 5.5 nM. The graphs show the mean number of H2AX-pSer139 nuclear foci/cell ± SEM from at least 40 counted cells/condition. <i>p</i> values in the Figure refer to two-tailed t-test.
regulation are observed in SK-N-SH cells with stable ATMS silencing, such signs are limited to a very small fraction of known MYCN regulated genes and are not observed across all the SK-N-SH or CLB-Ga cells with stable ATMS silencing considered.

To investigate the possibility that this depends on the level of N-myc expression, we compared the level of N-myc expressed by SK-N-SHkd-3650 cells to that expressed by a NB cell line known to carry MYCN amplification. For this analysis we chose the SK-N-DZ cell line, which is the one with the lowest level of N-myc protein expression, among the ones available in our laboratory (Figure 10F). Compared to SK-N-DZ cells, SK-N-SHkd-1463 cells or CLB-Gakd-1463 cells have an approximately 20-fold lower level of N-myc as assessed by scanning densitometry (Figure 10G). These results suggest that, although ATMS silencing consistently upregulates N-myc expression in SK-N-SH and CLB-Ga cells, this level of N-myc, or the entity of the upregulation, is not sufficient to trigger a typical MYCN target gene signature.

In the second set of experiments, we extended our analysis to the whole transcriptome of SK-N-SHkd-3650 and SK-N-SHkd-LacZ cells by cDNA microarray. Thirteen genes were found to be up- or downregulated by at least 2-fold (p < 0.01) in SK-N-SHkd-3650 cells compared to SK-N-SHkd-LacZ cells (COX17, TSTD1, ACOT1, ACOT2, MYD88, B2GALNT1, CD10, SHC1, ARMCX1, ZNF208, MAGEC2, BCHE, IMPA2). However, subsequent real-time quantitative validation of this mRNA signature in SK-N-SHkd-4351, CLB-GaLacZ, CLB-GaLkd-1463, and CLB-Gakd-3650 cells did not confirm consistent regulation of these genes by ATMS silencing across these different SK-N-SH or CLB-Ga stable transfectants.

As a next step, we performed experiments aiming at demonstrating more directly that the tumor promoting effect of ATMS silencing is not mediated by MYCN.

First, we assessed the sensitivity of SK-N-SH or CLB-Ga stable transfectant proliferation toward (+)-JQ1, a specific inhibitor of MYCN transcription and transcriptional activity that more markedly inhibits proliferation in NB cells with MYCN amplification than in NB cells without MYCN amplification [34]. In the soft agar assay, (+)-JQ1 inhibited cellular proliferation in SK-N-SH and CLB-Ga stable transfecnts with similar efficiency, independently of ATMS silencing (Figure 10H).

Second, we silenced the expression of ATMS in the GI-ME-N cell line. Similar to SK-N-SH and CLB-Ga cells, GI-ME-N cells have no amplification of MYCN and retain a functional ATM/p53 response to DNA damage [17, 35]. In addition, these cells have no detectable MYCN expression as assessed by Western Blotting and real-time quantitative PCR (ref. [35]; and see below).

GI-ME-N stable transfectants expressing ATMS shRNA 1463 (referred to as GI-ME-Nkd-1463) cells have a 6-fold reduction in ATMS protein expression compared to GI-ME-N cells expressing a LacZ control shRNA (referred to as GI-ME-NNkd-LacZ cells) whereas GI-ME-N cells expressing ATMS shRNA 3650 (referred to as GI-ME-Nkd-3650) exhibit an intermediate silencing of ATMS (Figure 11A). Similar to SK-N-SH and CLB-Ga cells, phosphorylation of p53-Ser15 and p21/WAF1 induction were reduced or delayed in GI-ME-Nkd-1463 and GI-ME-Nkd-3650 cells in response to NCS compared to GI-ME-Nkd-LacZ cells (Supplementary Figure S6). In the soft agar assay, GI-ME-Nkd-1463 and GI-ME-Nkd-3650 cells form colonies larger than those formed by GI-ME-Nkd-LacZ cells. Again, the effect was more marked in the subline having the strongest silencing of ATMS (GI-ME-Nkd-1463) (Figure 11B). When injected into nude mice, GI-ME-Nkd-1463 and GI-ME-Nkd-3650 cells formed tumors 33.6- and 9.3-fold larger, respectively, than those formed by GI-ME-Nkd-LacZ cells (Figure 11C). Ki67 immunostaining revealed increased proliferation in xenografts carrying ATMS silencing at the time of sacrifice (Figure 11D). No distant metastases were observed at the time of dissection or in the subsequent histological analysis (HE staining) in the brain, kidney, spleen, heart, liver, lung, lymph nodes or femurs of mice injected with GI-ME-Nkd-1463, GI-ME-Nkd-3650 or GI-ME-Nkd-LacZ cells.
MYCN expression was undetectable in GI-ME-Nkd-3650, GI-ME-Nkd-1463 and GI-ME-Nkd-LacZ cells by Western Blotting and real-time quantitative PCR (Figure 11E), thus further corroborating the conclusion that the tumor promoting effect of ATM silencing in the NB cell background does not require MYCN.

In summary, our results show (i) that ATM is frequently deleted in NB, and that deletion correlates with lower ATM expression, EFS and OS; (ii) that stable silencing of ATM by three different ATM shRNAs confers a growth advantage to three different NB cell lines in vitro and in vivo; (iii) that this effect is dependent on the extent of ATM silencing; (iv) that partial silencing of ATM is sufficient to observe such growth advantage, and (v) that this effect does not require the expression or the activity of MYCN.

**DISCUSSION**

The proportion of NB with 11q deletion is low in forms having a more favorable prognosis (localized and 4S stages), which represent 8 to 21% of NB cases. However, it is significantly higher in aggressive metastatic stage 4, where this alteration is observed in more than half of the tumors [2, 36]. Several studies reported an association between 11q aberrations and unfavorable outcome [2, 36–39] thus suggesting that patients presenting with localized and 4S stages NB and 11q deletion would benefit from a more intensive therapy. On this background, 11q deletion was recently added in the INRG classification as an independent prognostic marker, predicting poor outcome in a subset of cases with intermediate risk [2, 36, 40].
importance of 11q deletion as an independent prognostic marker is further highlighted by its capacity to predict poor prognosis in NB devoid of a typical MYCN target gene signature due to MYCN amplification or N-myc protein stabilization (ref. [5]; this paper). An intriguing finding is the inverse correlation of MYCN amplification and 11q deletion, with very infrequent cases described carrying both cytogenetic alterations. These cases are characterized by a dramatic decline of survival rates [36].

In addition to its prognostic value, 11q deletion might have functional implications in NB, possibly through the haploinsufficiency of tumor suppressor(s) contributing to the progression of this disease. Usually, 11q deletion involves a large distal part of the chromosome 11 spanning over 60 Mb from 11q13 to 11qter [2], but smaller deletions were also identified, leading to the identification of a shortest region of overlap (SRO). Different SRO were reported in sporadic NB, mostly at 11q23 (11q23.3 [37]; 11q14-q23 [41]; 11q23.3-q25 [42]), but no consensus region was found suggesting that there may be more than one 11q NB suppressor gene [43]. Other 11q NB suppressor genes might be TSLC1 (also named CADM1 or IGSF4), SDHD and H2AX [44–48].

Chromosome 11q deletion has been suggested to occur late after NB initiation [49] thus raising the possibility that it might contribute to the late phases of NB progression. If this hypothesis were confirmed by future data, it might explain why AT patients or carriers have not been reported to be at higher risk for NB. Well-established tumor suppressors are frequently mutated in somatic cancers which are not or rarely associated with germline mutations in the same genes. This is the case for TP53, mutated in approximately 60% of sporadic lung, ovary, bladder, intestine, and head and neck cancers, whose frequency exhibits little or no increase in the Li Fraumeni syndrome [50–52], or for ATM itself, frequently mutated in sporadic colon cancer (cancer.sanger.ac.uk/cancergenome/projects/cosmic/), not a typical hallmark of AT [7]. In these settings, ATM or TP53 inactivation is likely to contribute to the progression rather than to the initiation of these tumors. Initiating events in NB might include the gain of 17q, the most frequent genetic abnormality in NB (ref. [53], and references therein). Along the same lines, it is interesting to note that TP53, which works downstream of ATM, is rarely mutated in primary NB. Consistent with this notion, NB is rare in Li Fraumeni syndrome. However, TP53 is frequently mutated in NB relapses [16, 54, 55].

Based on our epidemiological data showing that reduced expression due to haploinsufficiency, rather than mutation, affects ATM status in NB, we generated NB cell lines with stable ATM silencing to investigate the possibility that reduction of ATM expression due to 11q deletion might contribute to NB progression. In the three NB cell lines considered, ATM silencing confers an in vitro and in vivo growth advantage as assessed on the basis of the soft agar assay and subcutaneous xenografts in nude mice. This effect could be due in part to the reduced basal levels of p21/WAF1 expression, consistently observed in the three NB cell lines with stable ATM silencing generated. In our model, ATM silencing does not seem to confer metastatic capacity to NB cells. However, metastasis of human cells in nude mice is infrequent. The consistency of our data across three different NB cell lines, the tumor progression effect resulting from partial ATM silencing and the MYCN independence of the phenotype observed suggest that 11q deletion is causally involved in NB progression and that ATM haploinsufficiency contributes to this effect.

These results provide experimental evidence that ATM deletion, an event frequently observed in NB with poor prognosis and not carrying MYCN amplification, might be causally involved in the progression of this NB tumor subset. From a clinical point of view, these data suggest that activation of branches of the ATM pathway by small molecule drugs (e.g. the p53 activator nutlin-3 [16, 56]) might be of benefit to patients carrying this particular subset of NB. Since 11q also carry additional genes regulating the DNA damage response (e.g. MRE11, H2AX) it is possible that simultaneous deletion of these genes contributes individually to the aggressive behavior of NB carrying 11q deletion, and that the poor prognosis of NB carrying 11q deletion results from the simultaneous inactivation of several tumor suppressors, ATM being one of them.

MATERIALS AND METHODS

Ethics statement

Investigation has been conducted in accordance with the ethical standards and according to the Declaration of Helsinki and according to national and international guidelines and has been approved by the authors’ institutional review board.

NB tumor sets

We used two distinct NB tumor sets. Fifty NB DNA samples (NB50) collected from children who, or their representatives, had consented to anonymous use in research were obtained from the Children’s Oncology Group Neuroblastoma Biology Committee. Twelve were stage 1, 8 were stage 2, 6 were stage 3 and 24 were stage 4 NB. DNA from 60 Caucasian blood donors without family history of cancer was used as control. The NB110 set is an extended set of NB88 [5] with samples from patients with NB of all stages. Written informed consent was obtained from patients’ parents in accordance with review board policies and procedures for research dealing with tumor specimen and clinical information. The medical ethics committee of the Academic Medical Center (AMC) in Amsterdam approved the study. All NB samples were derived from primary tumors.

www.impactjournals.com/oncotarget
of untreated patients. mRNA was isolated and analyzed using Affymetrix (Santa Clara, CA) Human Genome U133 Plus 2.0 arrays and were normalized using MAS5.0 (accession no. GSE16476). Genomic aberrations were scored by arrayCGH and/or cgCGH (coverage profiles of complete genomics sequencing data resulting in CGH-like plots [12]). We used a cut-off of -0.5 (2log) to score \( ATM \) loss. Data were analyzed using the R2 platform (http://r2.amc.nl).

Analysis of \( ATM \) alterations in NB samples and NB cell lines

We analyzed the DNA of 16 NB cell lines by standard FISH using a commercial \( ATM \) probe (Abbott, Baar, Switzerland). The 66 coding exons of the \( ATM \) gene were screened for mutations by DHPLC (Wave™ System, Transgenomic Inc., San Jose, CA, USA). Alterations detected by DHPLC were analyzed by direct sequencing [57]. To determine the relative copy number of the \( ATM \) exons, we analyzed large gene rearrangements by Multiplex Ligation-dependent Probe Amplification assay (MLPA; SALSA P041 and SALSA P042 ATM, MRC-Holland, The Netherlands) according to manufacturer’s instructions and as reported [58]. \( ATM \) methylation status was assessed by methylation specific MLPA assay (MS-MLPA, ME001B Tumor suppressor-1 and ME002 Tumor suppressor, MRC-Holland), according to manufacturer’s instructions and as reported [59].

Statistical considerations

For tests of association and survival analyses within the NB50 series, clinical data of 49 patients were included (one patient was excluded because of \( ATM \) duplication). For EFS, time to event was calculated from diagnosis until the first occurrence of relapse, progression, secondary malignancy, or death from any cause, or until last contact if no event occurred. For OS, time from diagnosis to death was calculated, or until last contact if the patient was alive. Curves were compared using a logrank test.

In the NB110 series, EFS was calculated in the same way as in the NB50 series, the only difference being that those events where the ‘death reason’ was specified as being a toxic death were removed. Cox regression analyses were performed in R, using the coxph() function of the survival library with either 1 or 2 covariates.

Cell culture

NB cell lines were cultured as described [59]. The soft agar assay was performed as described [14].

\( ATM \) silencing

Stable silencing of \( ATM \) was achieved by stably transfecting NB cell lines with pSuper-neo (Oligoengine, Seattle, Washington, USA) expressing shRNA targeting LacZ mRNA (CGACUACAACAAU CAGCGA) or three different \( ATM \) mRNA sequences (1463: GAUACCAGAUUUUGGA GAU; 3650: GCUGCAGAGUUCAAUAGA; 4351: GCAACUUUGCCAUUAUCA). Stable transfectants were selected in G418 according to pSuper-neo manufacturer’s instructions.

Quantitative real-time PCR

Quantitative real-time PCR was performed as described [14]. Primer sequences were as follows:

\[
\begin{align*}
\text{ATM:} & \quad \text{TGGTGAACATCATCACAAGTTC; TCTCCCTCTGTCCTGGAA} \\
\text{MYCN:} & \quad \text{CCTCCGGTCCAGTTTCTCA; GCTTCTCATCTTTTACC} \\
\text{ALK:} & \quad \text{CCCCGCTTCTCTTCCA; GGCACTTTGTGATCC} \\
\text{PHOX2B:} & \quad \text{GTCGATCCGCAGGCTTTCC; GCTTGCTTCTCTTTGAG} \\
\text{MTAP:} & \quad \text{CCCCAAACGAGAGAGGTTCT; GCACCGAGATCTTCTTA} \\
\text{PRMT1:} & \quad \text{GCAGATCTACGTCGGGTAC; TCTACCCGATACTACTCG} \\
\text{PTMA:} & \quad \text{GATGACACGCGCTTCCTC; CTGGTCAAATTTCTCAGTGGTTG} \\
\text{CLU:} & \quad \text{TGGGCCGCCAGTCTTGA; AGAGTTGAGGGCGAGCTTCT} \\
\end{align*}
\]

Western blotting

Western Blotting and densitometry for \( ATM \), \( \beta\)-actin, NBS1, NBS1-pSer343 or N-my c were as described [14]. Western Blotting for N-myc, p53-pSer15, p53 or p21/WAF1 used antibody sc-53993 (Santa Cruz Biotechnology (Dallas, Texas, USA)), 9284 (Cell Signaling Technology), DO-1/sc-126 (Santa Cruz Biotechnology) or SX118/sc-53870 (Santa Cruz Biotechnology) respectively. Second antibody/HRP complexes were revealed with Roche Lumi-Light (Cat. No. 12015200001) or Lumi-Light Plus (Cat. No. 12015218001) Western Blotting Substrate, depending on the level of sensitivity required. Blots were scanned with a Hewlett-Packard 1536dnf scanner and imported using Microsoft Fax and Scan v. 6.1.

Xenografts

Five million cells were resuspended in Growth Factor Reduced Matrigel (cat. No. 354230, VWR International GmbH, Dietikon, Switzerland) and injected subcutaneously into the flank of 6 weeks-old Swiss nude female mice (Charles River Laboratories, L’Arbresle Cedex, France). Five mice/condition were used. Mice were maintained in a specific pathogen free facility. Experiments were performed according to Institutional ethics guidelines and to the Swiss law.
ATM and Ki-67 immunohistochemistry

FFPE Tissue sections were deparaffinized and rehydrated using standard procedures. Heat-induced epitope retrieval was carried out in a BioCare Medical (Concord, CA, USA) pressure cooker (Decloaking ChamberTM NxGen) with 10mM citrate buffer (pH 6.0) at 110°C for 12 min. Samples were incubated with a rabbit anti-Ki67 antibody (ab16667, Abcam, UK, diluted 1:100), or a rabbit anti-ATM antibody (ab32420, Abcam, UK, diluted 1:200) respectively 1 hour at RT or overnight at 4°C in a moist chamber. The signal was revealed with MACH 4 Universal HRP-Polymer Detection Kit (BioCare) according to the manufacturer’s instructions. Purified rabbit IgG (02–6102, Life Technologies, Switzerland) was used as a negative control. Stained sections were photographed with a Zeiss Axio Vert.A1 microscope. Images were imported with AxioVision v. 4.8.2.0.

Flow cytometry

Apoptosis was measured by flow cytometry using the Annexin V apoptosis detection Kit (BD Pharmingen cat. no. 556547) according to manufacturer’s instructions. Cell cycle analysis used the BD Pharmingen BrdU Flow Kit (cat. no. 552598). Cells were labelled with 20 μM 5-bromo-2′-deoxyuridine (BrdU) for 4 h. After BrdU incorporation, cells were stained according to manufacturer’s protocol. BrdU was omitted in the negative control.

All the data were collected with a Beckman Coulter FACS CyAn analyzer. Analyses were performed with Kalusa software (Beckman Coulter).

γ-H2AX immunofluorescence

Immunofluorescence with phospho-Ser139 H2AX antibody JBW301 (catalogue no. 05–636, Millipore, Zug, Switzerland) was performed as described [60].

ACKNOWLEDGMENTS

We thank Dr. V. Combaret and the Centre de Ressources Biologiques du Centre Léon BERARD for providing the CLB-Ga cell line; Dr. V. Combaret for critically reading the manuscript; C. Barraclough and Drs. O. Schaad and M. Docquier of the iGE3 genomics platform of the University of Geneva for producing and analyzing the real-time quantitative PCR and cDNA microarray data; Dr. V. Favaudon for providing neocarzinostatin; Drs. J.-M. Joseph and N. Gross for discussions. This study was supported by grants from the following Foundations: CANSEARCH, Hans Wilsdorf, Le Printemps des Enfants, Fondation pour la lutte contre le cancer et pour des recherches médico-biologiques, Carigest, Association Hubert Gouin – Enfance & Cancer, the Ligue Génevoise contre le Cancer, the Tom Voûte Fund and Kinderen Kankervrij (KIKKA) Foundation, and the Children’s Oncology Group (Grant U10-CA98413-06). The authors declare no conflict of interest in relation to the work presented in this study.

REFERENCES


